INCLINE VILLAGE, Nev.,
June 25, 2019 /PRNewswire/
-- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI)
today announced the resignation of Chief Financial Officer,
Peter Garcia, who will be leaving
the Company effective August 15,
2019. He will continue in his role through the filing of the
Company's second quarter 10-Q in August and is committed to ensure
a smooth transition of duties.
Since joining PDL in May 2013, Mr.
Garcia played an instrumental role in successfully completing the
Company's convertible debt transactions, achieving an improved
capital structure for the Company, and building a quality finance
and accounting team.
"On behalf of the Company's board of directors and the
management team, I'd like to thank Pete for his leadership and many
contributions during his time at PDL," said Dominique Monnet, president and CEO of PDL.
"Pete's legacy is positioning us for success as we execute our
business strategy of building a portfolio of actively managed
healthcare assets. We wish Pete well as he pursues his personal
goals." The Company is retaining an executive search firm to lead
the search for his replacement.
About PDL BioPharma, Inc.
PDL's mission is to improve the lives of patients and create
value for our shareholders and our people by applying our capital
and expertise for the successful development and commercialization
of innovative therapeutics by our partner companies. We deliver on
our mission by entering into strategic transactions involving
innovative late clinical-stage or early commercial-stage
therapeutics with attractive revenue growth potential.
NOTE: PDL, PDL BioPharma, the PDL logo and associated logos
and the PDL BioPharma logo are trademarks or registered trademarks
of, and are proprietary to, PDL BioPharma, Inc. which reserves all
rights therein.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-announces-departure-of-cfo-300874794.html
SOURCE PDL BioPharma, Inc.